2024
Evaluation of large language models as a diagnostic aid for complex medical cases
Ríos-Hoyo A, Shan N, Li A, Pearson A, Pusztai L, Howard F. Evaluation of large language models as a diagnostic aid for complex medical cases. Frontiers In Medicine 2024, 11: 1380148. PMID: 38966538, PMCID: PMC11222590, DOI: 10.3389/fmed.2024.1380148.Peer-Reviewed Original ResearchClinical casesLanguage modelHospital case recordsConsecutive clinical casesDifferential diagnosis listComplex clinical casesDifferential diagnosisDiagnostic considerationsCase discussionDiagnostic aidCase recordsDiagnosisComplex medical casesDiagnosis listDifferential listMedical specialtiesMedical professionalsDiseaseIncidence
2023
De Novo Oligometastatic Breast Cancer
Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2023, 41: 5237-5241. PMID: 37607325, PMCID: PMC10691789, DOI: 10.1200/jco.23.00911.Peer-Reviewed Original ResearchP018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy
Bardia A, Pusztai L, Albain K, Kalinsky K, Hershman D, Barlow W, Tokunaga E, Ciruelos E, Loirat D, Isaacs C, Testa L, Dry H, Kozarski R, Maxwell M, Harbeck N, Sharma P. P018 TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd) ± durvalumab vs investigator’s choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease following neoadjuvant therapy. The Breast 2023, 68: s23. DOI: 10.1016/s0960-9776(23)00137-6.Peer-Reviewed Original Research
2022
Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
Huppert L, Rugo H, Pusztai L, Mukhtar R, Chien A, Yau C, Wolf D, Berry D, van 't Veer L, Yee D, DeMichele A, Esserman L, Consortium I. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. Journal Of Clinical Oncology 2022, 40: 504-504. DOI: 10.1200/jco.2022.40.16_suppl.504.Peer-Reviewed Original ResearchI-SPY2 trialInvestigational agentsMolecular subtypesNodal statusPathologic complete response rateMultiple investigational agentsComplete response ratePhase 3 trialHER2- breast cancerLuminal statusNeoadjuvant therapyPrimary endpointImmune signaturesPCR rateTreatment armsHeterogenous diseaseBC therapySubtype 5Breast cancerImmune biologyResponse ratePembrolizumabHormone receptorsDiseaseTrials
2016
Patient preferences regarding incidental genomic findings discovered during tumor profiling
Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, Goldberg SB, Pusztai L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling. Cancer 2016, 122: 1588-1597. PMID: 26970385, DOI: 10.1002/cncr.29951.Peer-Reviewed Original ResearchConceptsIncidental findingTumor profilingGermline variantsAmbulatory oncology clinicsMajority of patientsStandard of careTumor profiling testsOncology clinicPreventable diseaseFamily historyPatient tumorsInformation patientsPreventable illnessPatientsDisease variablesUnpreventable diseaseUncertain significanceDisclosure preferencesCancerFrequent concernTumorsIllnessProfiling testsDiseaseCurrent study
2015
Tumor profiling and the incidentalome: patient decisions and risks
Hofstatter E, Mehra K, Yushak M, Pusztai L. Tumor profiling and the incidentalome: patient decisions and risks. Future Oncology 2015, 11: 3299-3305. PMID: 26562094, DOI: 10.2217/fon.15.260.BooksConceptsTumor profilingField of oncologyTumor DNA sequencesOncology patientsIncidental discoveryPatient educationPatient's perspectivePatient decisionOncology communityClinical implicationsPatient healthGermline mutationsCancer medicineGenetic sequencingCancer therapyTherapyPotential riskRiskHealthPatientsIncidentalomeMainstayDiseaseOncologyProfiling
2011
Gene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet 2011, 378: 1812-1823. PMID: 22098854, DOI: 10.1016/s0140-6736(11)61539-0.Peer-Reviewed Original ResearchConceptsBreast cancerER-negative breast cancerGene expression profilingER-positive diseasePrognosis of patientsDistinct molecular aberrationsMolecular classification systemPotential clinical useClinical behaviorHistological featuresClinical trialsMolecular subtypesProliferation-related genesMultigene classifiersClinical practiceMolecular aberrationsExpression profilingCancerDistinct diseasesMultigene predictorsClinical useMolecular classificationDiseaseHeterogeneous groupDifferent diseases
2007
New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer
Pusztai L, Cristofanilli M, Paik S. New Generation of Molecular Prognostic and Predictive Tests for Breast Cancer. Seminars In Oncology 2007, 34: s10-s16. PMID: 17512431, DOI: 10.1053/j.seminoncol.2007.03.015.Peer-Reviewed Original ResearchConceptsBreast cancerBreast cancer careDifferent clinical coursesAvailable diagnostic assaysTrial-based approachClinical coursePrognostic predictorCancer carePrognostic informationSimilar tumorsMolecular PrognosticHeterogeneous diseaseTumor cellsCancerPredictive testDiagnostic assaysNovel diagnosticsMolecular analytical techniquesMolecular differencesImportant advancesMolecular analysisPatientsDiagnostic companiesTumorsDiseaseBreast Cancer
Ross J, Linette G, Stec J, Clark E, Ayers M, Symmans F, Hortobagyi G, Pusztai L. Breast Cancer. 2007, 269-278. DOI: 10.1007/978-0-387-33227-7_24.Peer-Reviewed Original ResearchBreast cancerInvasive breast cancerCurrent incidence ratesAmerican womenGenetic predisposition testingMicrometastasis detectionSitu diseaseClinical managementIncidence rateField of pharmacogenomicsRNA expression profilingNew casesPredisposition testingCancerMolecular pathologyBiomarker assaysSerum diagnosticsDiseaseWomenExpression profilingFuture assaysAssaysPathology
2006
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nature Reviews Clinical Oncology 2006, 3: 621-632. PMID: 17080180, DOI: 10.1038/ncponc0636.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapyMolecular classificationBreast cancerER-positive tumorsEarly-stage diseaseNew molecular classificationRoutine clinical useAdjuvant therapyNegative diseaseEstrogen receptorIndividual patientsChemotherapyClinical usePatientsCancerDiseaseMolecular characteristicsFuture promiseTherapyTumorsReceptorsHétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d’une chimiothérapie adjuvante?
André F, Pusztai L. Hétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d’une chimiothérapie adjuvante? Oncologie 2006, 8: 235-242. DOI: 10.1007/s10269-006-0382-6.Peer-Reviewed Original ResearchThe new staging classification: is it useful for clinicians? S Eva Singletary
Pusztai L. The new staging classification: is it useful for clinicians? S Eva Singletary. 2006, 79-92. DOI: 10.1201/b13912-6.Peer-Reviewed Original Research
2005
Breast Cancer Biomarkers
Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Breast Cancer Biomarkers. Advances In Clinical Chemistry 2005, 40: 99-125. PMID: 16355921, DOI: 10.1016/s0065-2423(05)40003-7.Peer-Reviewed Original Research
2004
Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma
Gonzalez‐Angulo A, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004, 101: 258-263. PMID: 15241821, DOI: 10.1002/cncr.20348.Peer-Reviewed Original ResearchConceptsEarly-stage breast carcinomaBreast carcinomaTumor specimensPathologic responseStage II breast carcinomaAJCC stage IIMedian patient ageStage III diseasePathologic complete responseOverall survival rateLack of associationGene amplificationPreoperative chemotherapyRecurrent diseaseComplete responsePatient agePatientsCarcinomaSurvival rateTissue specimensStage IITaxanesHormone receptorsTumorsDisease